Cutting-edge healthcare solution now in Nigeria as Syndicate Bio Launch Direct by Syndicate Bio to provide genomic insights to patients

Syndicate Bio has announced the debut of Direct by Syndicate Bio, a groundbreaking genetic testing and precision medicine service designed to provide actionable genomic insights to patients, healthcare providers, and consumers across Africa. The launch coincides with the opening of a state-of-the-art sequencing laboratory in Lagos, which delivers world-class genomic and multi-omics testing powered by artificial intelligence (AI). This new facility will bring locally accessible, cutting-edge healthcare solutions to Nigeria’s over 200 million citizens and the wider global diaspora.

Raising the Standard for Genomic Medicine in Africa

The Lagos laboratory establishes a new benchmark for precision medicine on the continent. Outfitted with next-generation sequencing (NGS) technology and advanced molecular analysis systems, it supports both clinical-grade testing and research while ensuring faster turnaround times for healthcare providers, researchers, and patients.

Nigeria’s immense ethnic diversity has produced unique genetic variations and drug metabolism profiles. By integrating genomics, transcriptomics, and metabolomics with AI-driven analytics, Direct by Syndicate Bio aims to identify biomarkers that reflect these population-specific traits—contributing to better diagnosis, prevention, and treatment for Nigerians and millions with shared ancestry worldwide.

Launch Event and Stakeholder Engagement

The launch event, hosted at the Lagos facility, brought together key figures from Nigeria’s medical and scientific communities, including representatives from the National Institute for Cancer Research and Treatment (NICRAT), Lakeshore Cancer Center, Redus Center for Digestive Health, Beacon Health, Healthtracka, Society for Family Health, and Atlantis Pediatric Hospital. Attendees joined Dr. Abasi Ene-Obong, Founder of Syndicate Bio, for a guided tour and an overview of the Direct platform.

Dr. Ene-Obong stated:

“Nigeria’s diversity presents both challenges and opportunities for precision medicine. The lack of locally sourced genomic data has long hindered our ability to prevent, diagnose, and treat disease effectively. With Direct, we’re leveraging Nigeria’s genetic richness to generate insights that will enhance care for Nigerians and the diaspora while advancing inclusive precision medicine globally.”

A Comprehensive Portfolio of Tests

Direct by Syndicate Bio launches with a broad suite of tests addressing critical health priorities:

• Hereditary Cancer Testing: Analysis of 300+ genes, including BRCA1/2, linked to cancers such as breast, ovarian, pancreatic, prostate, and colorectal.
• Hereditary Conditions Testing: Screening for 90 inherited disorders affecting cardiovascular, metabolic, hematological, neurodevelopmental, ophthalmological, and immune systems.
• Health & Wellness Testing: 80+ genes associated with nutrition, metabolism, fitness, sleep, immunity, skin health, and lifestyle traits.
• Somatic Oncology Panels: Comprehensive tumor profiling for precision-guided cancer therapy.
• Non-Invasive Prenatal Testing (NIPT): Safe, early evaluation of fetal health.
• Pharmacogenomics: Tailored drug selection and dosing based on individual genetic makeup.
• Population-Relevant Traits: Testing for conditions such as sickle cell disease, thalassemia, G6PD deficiency, and hemophilia A/B.
• NGS-Based Testing: Advanced next-generation sequencing to generate high-resolution data despite limited African reference genomes.

All results are delivered in a clinician-ready format, supported by professional genetic counselling, with strict compliance to global standards for data privacy, quality assurance, and patient safety.

The Direct Nigeria Precision Medicine Network (DNPMN)

To drive clinical adoption, Syndicate Bio has launched the Direct Nigeria Precision Medicine Network (DNPMN) in collaboration with top institutions. The network will convene a multidisciplinary tumor board to promote collaboration, second opinions, and knowledge exchange between Nigerian and international experts.

Key Partners Include:

• Lakeshore Cancer Center: Nigeria’s foremost oncology center providing advanced diagnostics and integrated care.
• Redus Center for Digestive Health: A leader in gastrointestinal and pancreatobiliary medicine, home to Nigeria’s first endoscopic ultrasound program.
• Roswell Park Comprehensive Cancer Center (USA): An NCI-designated center recognized among America’s top cancer research and treatment facilities.

Through the DNPMN, patients and families will gain access to personalized prevention strategies, interventional procedures, and precision-guided treatments informed by genomic insights.

Partner Perspectives

Dr. Sai Yendamuri, Chief Strategy Officer, Roswell Park Comprehensive Cancer Center, noted:

“We are honored to collaborate with Syndicate Bio in bringing precision medicine to underserved communities in Africa. Together, we will combine genomic research with clinical education and cancer awareness to improve patient outcomes. Our joint tumor board will deepen this partnership by fostering collaboration, advancing innovation, and enhancing patient care.”

Dr. Chukwumere Nwogu, Co-Founder & CEO, Lakeshore Cancer Center, added:

“This partnership allows us to deliver precision oncology that reflects the genetic realities of our patients. It represents a major step forward for data-driven cancer care in Nigeria.”

Dr. Kenechukwu Chudy-Onwugaje, Founder & CEO, Redus Center for Digestive Health, emphasized:

“Digestive cancers are a growing concern in Nigeria. Understanding genomic variations will transform how we diagnose and treat these conditions. Direct by Syndicate Bio gives clinicians the data-driven tools needed to elevate care nationwide.”

With Direct by Syndicate Bio, Africa’s most populous nation takes a decisive leap toward locally powered, globally relevant precision medicine, paving the way for more equitable healthcare innovation and genomic inclusion.